Summary of Clinical Use

Approved to treat multicentric Castleman's disease (MCD, a.k.a. giant lymph node hyperplasia), a rare blood disorder. SARS-CoV-2 and COVID-19: Siltuximab is being investigated as a mechanism to combat cytokine storm resulting from an exaggerated response of the immune system in patients with severe COVID-19.

Mechanism Of Action and Pharmacodynamic Effects

Interleukin-6 (IL-6) has emerged as a key factor in the pathogenesis of multicentric Castleman’s disease (MCD) [3]. Siltuximab is an anti-IL-6 monoclonal antibody which ameliorates the IL-6-induced increase in immunoglobulin-producing cells and production of acute phase proteins associated with MCD [2].

Clinical Trials
Clinical Trial ID	Title	Type	Source	Comment	References
NCT04329650	Efficacy and Safety of Siltuximab vs. Corticosteroids in Hospitalized Patients With COVID-19 Pneumonia	Phase 2 Interventional	Fundacion Clinic per a la Recerca Biomédica
NCT04330638	Treatment of COVID-19 Patients With Anti-interleukin Drugs	Phase 3 Interventional	University Hospital, Ghent

External links

For extended ADME data see the following: Electronic Medicines Compendium (eMC) Drugs.com European Medicines Agency (EMA)